Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993908 | 1.00 | CPN1 (0.39) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL5993912 | 1.00 | CPN1 (0.39) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL14167608 | 0.88 | CPN1 (0.37) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL22233424 | 0.88 | CPN1 (0.37) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL25258283 | 0.88 | CPN1 (0.37) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL25291875 | 0.88 | CPN1 (0.37) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL12411234 | 0.84 | CPN1 (0.40) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL28856946 | 0.84 | HRH3 (0.46) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL15140789 | 0.83 | MEN1 (0.42) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27577125 | 0.83 | CPN1 (0.39) | CPN1CPB2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1602196-A | Ureas of 2-aminobenzothiazoles as adenosine modulators | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1602196-A | Ureas of 2-aminobenzothiazoles as adenosine modulators | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | disclosed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | disclosed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | CPN1 3752/4885CPB2 2328/4885ALDH1A1 512/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | CPN1 3752/4885CPB2 2328/4885ALDH1A1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.